immatics' Renal Cancer Vaccine IMA901 Completes Phase 3 Patient Recruitment and is Granted US Orphan Drug Designation by the FDA

immatics' Renal Cancer Vaccine IMA901 Completes Phase 3 Patient Recruitment and is Granted US Orphan Drug Designation by the FDA PR Newswire TUEBINGEN, Germany, November 8, 2012 TUEBINGEN, Germany, November 8, 2012 /PRNewswire/ -- immatics biotechnologies GmbH, a biopharmaceutical company developing rationally designed therapeutic vaccines that are active against cancer, announced today that it has completed patient recruitment into the pivotal phase 3 trial evaluating its lead cancer vaccine IMA901 for renal cell carcinoma (RCC). The trial has completed patient inclusion and it is expected that around 345 patients will be randomized across 10 countries in the US and Europe. The first (interim) overall survival results are expected during the first half of 2014. The phase 3 IMPRINT trial* is designed to show an overall survival benefit with IMA901 in combination with sunitinib (Sutent®, Pfizer), standard first-line therapy in comparison to sunitinib alone in patients with metastatic and/or locally advanced RCC. The secondary endpoints include immune response to the peptides contained in IMA901, progression- free survival, safety and tolerability. The study aims to build on the promising survival and immune response data observed in the phase 2 study with IMA901 in advanced RCC patients. These data show that patients who produced an immune response to two or more of the tumor-associated peptides (TUMAPs) contained in IMA901 had a significantly longer survival.